Nanogrow Biotech

Startup Competition
Nanogrow Biotech is a biotechnology company focused on developing a new generation of biological therapies based on camelid single-domain antibodies (VHHs or nanobodies) for the treatment of immune-mediated diseases and cancer. Nanogrow develops nanobody-based therapies that retain the potency of modern biologics while enabling localized administration, thereby minimizing systemic exposure and expanding patient eligibility for biological treatments. Nanobodies are the smallest and most stable antibody molecules known. Their exceptional physicochemical stability enables formulation across multiple delivery routes (oral, topical, inhaled/nebulized, intratumoral or injectable), unlocking targeted therapies with reduced systemic toxicity. Nanogrow’s activity is built on an integrated bioengineering platform that spans the entire development cycle of a therapeutic nanobody—from target selection to final formulation.